Is It Too Late To Reassess Praxis Precision Medicines (PRAX) After Its 1-Year Surge?
“Praxis Precision Medicines has seen its stock soar over 338% in the past year, driven by positive late-stage trial results and a robust pipeline targeting CNS disorders. With two NDAs planned for early 2026 and a strong cash position, analysts maintain a strong buy consensus, though ongoing losses and high volatility pose risks for new … Read more